Acid Lactase in Combination With Yoghurt Bacteria for Improvement of Lactose Digestion in Lactose Malabsorbers

NCT ID: NCT01593631

Last Updated: 2012-05-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fermented dairy products, especially real Yoghurt, are often tolerated better by lactose malabsorbers than unfermented dairy products. The intake of dietary supplements containing acid Lactase derived from Aspergillus oryzae with lactose containing foodstuffs is known to reduce/alleviate symptoms of lactose intolerance in lactose malabsorbers. The study aims to compare the effect of the intake of a combination of yoghurt bacteria and acid lactase to the effect of yogurt bacteria or acid lactase alone on the lactose digestion in lactose malabsorbers. It is hypothized that the combination preparation will be more effective and/or will show a more reliable effect than the two mono-preparations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lactose Malabsorption

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2 billion lyoph. yoghurt bacteria

Group Type ACTIVE_COMPARATOR

Lyoph. yoghurt bacteria

Intervention Type DIETARY_SUPPLEMENT

capsules containing 2 billion lyoph. yoghurt bacteria

3300 FCC acid lactase

Group Type ACTIVE_COMPARATOR

Acid lactase

Intervention Type DIETARY_SUPPLEMENT

capsules cotaining 3300 FCC units of acid lactase

9000 FCC acid lactase

Group Type ACTIVE_COMPARATOR

Acid lactase

Intervention Type DIETARY_SUPPLEMENT

capsules containing 9000 FCC of acid lactase

Combination of Substances of arm 1 and 2

Group Type ACTIVE_COMPARATOR

Acid lactase plus yoghurt bacteria

Intervention Type DIETARY_SUPPLEMENT

Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Capsules containing di-calcium-phosphate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acid lactase

capsules cotaining 3300 FCC units of acid lactase

Intervention Type DIETARY_SUPPLEMENT

Acid lactase

capsules containing 9000 FCC of acid lactase

Intervention Type DIETARY_SUPPLEMENT

Lyoph. yoghurt bacteria

capsules containing 2 billion lyoph. yoghurt bacteria

Intervention Type DIETARY_SUPPLEMENT

Acid lactase plus yoghurt bacteria

Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria

Intervention Type DIETARY_SUPPLEMENT

Placebo

Capsules containing di-calcium-phosphate

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects of African or Asian origin.
* Older than 18 years
* Written informed consent

Exclusion Criteria

* Participation in a clinical study with a drug or a medical product withing the last 30 days;
* Inability to comply with the study protocol;
* Allergy to milk protein;
* Intolerance against lactase preparations;
* Known metabolic or gastrointestinal diseases which affect the absorption, metabolism or excretion of food components except lactose maldigestion;
* Intake of drugs influencing resorption of food components or gastrointestinal motility;
* Surgery within the last three months which still affect the current status of health;
* Psychiatric diseases
* Epilepsia
* Risk for suicide
* Eating disorders, e.g. anorexia, bulimia
* Alcohol or drug abuse
* Legal incapacity
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vitacare Gmbh & Co. KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

tecura GmbH Medicine & Biotechnics - Dept. of Clinical Research

Kiel, Schleswig-Holstein, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

de Vrese M, Laue C, Offick B, Soeth E, Repenning F, Thoss A, Schrezenmeir J. A combination of acid lactase from Aspergillus oryzae and yogurt bacteria improves lactose digestion in lactose maldigesters synergistically: A randomized, controlled, double-blind cross-over trial. Clin Nutr. 2015 Jun;34(3):394-9. doi: 10.1016/j.clnu.2014.06.012. Epub 2014 Jul 8.

Reference Type DERIVED
PMID: 25042846 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

120506000

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tolerance of a Probiotic Formula
NCT03925558 COMPLETED NA